# Anhui Zhifei Longcom Biologic Pharmacy trials: 49 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 49 trials with Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.: 49 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/anhui-zhifei-longcom-biologic-pharmacy-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 49
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 49, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07920172 | Clinical Trial of Recombinant Herpes Zoster Vaccine (ZFA01 Adjuvant, CHO Cells) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 1/2 | Recruiting | Herpes Zoster | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920172) |
| May 14, 2026 | NCT07587164 | C-TST for Diagnosis of Latent Mycobacterium Tuberculosis Infection in Indonesia | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Not applicable | Completed | Latent Tuberculosis Infection (LTBI) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07587164) |
| May 16, 2025 | NCT06975774 | Phase II Clinical Clical of the Pure Protein Derivatives of BCG | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 1 | Completed | Tuberculosis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06975774) |
| February 13, 2025 | NCT06824519 | Clinical Trials of Quadrivalent Influenza Vaccine | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 1/2 | Recruiting | Influenza, Human | 620 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06824519) |
| December 24, 2024 | NCT06747455 | BCG for Therapeutic Use Phase Ⅲ Clinical Trial | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 3 | Active not recruiting | BCG | 439 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06747455) |
| July 29, 2024 | NCT06524947 | Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 3 | Active not recruiting | Acute Gastroenteropathy Due to Norovirus | 6,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06524947) |
| October 25, 2023 | NCT06100653 | BCG for Therapeutic Use Phase I Clinical Trial | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 1 | Completed | Non-muscular Invasive Bladder Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06100653) |
| October 11, 2023 | NCT06078423 | A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 3 | Completed | Rabies Vaccine Adverse Reaction | 1,880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06078423) |
| September 21, 2023 | NCT06043388 | Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 1 | Unknown | COVID-19 | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06043388) |
| September 6, 2023 | NCT06025812 | Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Not applicable | Unknown | Coronavirus | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06025812) |
| June 12, 2023 | NCT05899179 | Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 3 | Completed | Latent Tuberculosis Infection | 780 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05899179) |
| June 8, 2023 | NCT05895110 | To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for... | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Not applicable | Completed | COVID-19 | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05895110) |
| June 6, 2023 | NCT05890521 | Safety Study of COVID19 Vaccine on the Market | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 4 | Unknown | COVID-19 | 100,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05890521) |
| May 9, 2023 | NCT05850507 | Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Not applicable | Completed | Coronavirus | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05850507) |
| February 28, 2023 | NCT05746611 | Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 4 | Completed | Latent Tuberculosis Infection | 7,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05746611) |
| January 11, 2023 | NCT05680415 | Clinical Trial of Mica | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 4 | Active not recruiting | Latent Tuberculosis Infection | 6,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05680415) |
| December 8, 2022 | NCT05642078 | Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 3 | Completed | Prevention of Influenza | 2,550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05642078) |
| November 15, 2022 | NCT05616754 | A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 3 | Unknown | COVID-19 | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05616754) |
| October 12, 2022 | NCT05574985 | Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Not applicable | Completed | COVID-19 | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05574985) |
| March 17, 2022 | NCT05284812 | A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 2 | Suspended | Tuberculosis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05284812) |
| January 24, 2022 | NCT05205096 | Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 1/2 | Completed | COVID-19 | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05205096) |
| January 24, 2022 | NCT05205083 | Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 1/2 | Unknown | COVID-19 | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05205083) |
| January 20, 2022 | NCT05198102 | ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 1/2 | Completed | Prevention of COVID-19 | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05198102) |
| January 20, 2022 | NCT05198063 | ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 1/2 | Completed | Prevention of COVID-19 | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05198063) |
| November 22, 2021 | NCT05128643 | Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 3 | Unknown | Coronavirus Disease 2019 | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05128643) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 1/2 | 7 |
| Phase 2 | 6 |
| Phase 3 | 15 |
| Phase 4 | 3 |
| Not applicable | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 30 |
| Unknown | 12 |
| Active not recruiting | 4 |
| Recruiting | 2 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Tuberculosis | 14 |
| COVID-19 | 12 |
| Coronavirus Infections | 6 |
| Latent Tuberculosis | 4 |
| Influenza, Human | 1 |
| Herpes Zoster | 1 |
| Urinary Bladder Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Sleep medicine clinics in the United States](https://specstream.ai/data/businesses/sleep-medicine-clinics/united-states)
- [Medical research institutes in the United States](https://specstream.ai/data/businesses/medical-research-institutes/united-states)
- [Fabric wholesalers in the United States](https://specstream.ai/data/businesses/fabric-wholesalers/united-states)
- [Basque restaurants in the United States](https://specstream.ai/data/businesses/basque-restaurants/united-states)
- [Tableware suppliers in the United States](https://specstream.ai/data/businesses/tableware-suppliers/united-states)
- [Nursing schools in the United States](https://specstream.ai/data/businesses/nursing-schools/united-states)
